Table 1 Characteristics of adverse event reports
Saxagliptin (%) | Sitagliptin (%) | Linagliptin (%) | Vildagliptin (%) | |
|---|---|---|---|---|
Number of events | 680 | 7811 | 802 | 347 |
Gender | ||||
Female | 313 (46) | 3703 (47) | 379 (47) | 159 (46) |
Male | 340 (50) | 3233 (41) | 360 (45) | 171 (49) |
Unknown | 27 (4) | 875 (11) | 63 (8) | 17 (5) |
Age (year) | ||||
<18 | 0 (0) | 8 (0) | 3 (0) | 0 (0) |
18–44 | 35 (5) | 39 (0) | 31 (4) | 18 (5) |
45–64 | 273 (40) | 2286 (29) | 169 (21) | 91 (26) |
65–74 | 143 (21) | 3386 (43) | 166 (21) | 70 (20) |
≥ 75 | 98 (14) | 1000 (13) | 171 (21) | 82 (24) |
Unknown | 131 (19) | 1092 (14) | 262 (33) | 86 (25) |
Outcome of AEs | ||||
Hospitalization (initial or prolonged) | 188 (28) | 2198 (28) | 253 (32) | 149 (43) |
Disability | 18 (3) | 373 (5) | 30 (4) | 11 (3) |
Life-threatening | 23 (3) | 473 (6) | 36 (4) | 21 (6) |
Death | 25 (4) | 483 (6) | 37 (5) | 50 (14) |